TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Investigating the Clinical Consequences of Flutemetamol-PET-scanning

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Dementia expert considers an Amyloid-scan appropriate according to Amyloid-imaging task force criteria (AIT) after conference with an Amyloid-PET expert~* Preambles of the AIT-Criteria are fulfilled~  1. A cognitive complaint with objectively confirmed impairment~ 2. AD as a possible diagnosis, but when the diagnosis is uncertain after a comprehensive evaluation by a dementia expert~ 3. When knowledge of the presence or absence of Abeta pathology is expected to increase diagnostic certainty and alter Management~  <!-- -->~  1. Patients with persistent or progressive unexplained MCI~ 2. Patients satisfying core clinical criteria for possible AD because of unclear clinical presentation, either an atypical clinical course or an etiologically mixed presentation~ 3. Patients with progressive dementia and atypically early age of onset (65 years or less in age)~ 4. other situations where preambles of AIT-Criteria are fulfilled~* Diagnosis was established in a memory clinic or by an experienced physician in dementia diagnostics~* The diagnostic procedures comprise in minimum MRI, neuropsychology, routine blood test for exclusion of symptomatic causes~* MMSE \>15~* Competency to consent~* Trial partner willing to support study physician~* Written informed consent by both patient and trial partner~* Understanding of German language~* Treating physician willing to collaborate with the study team~Exclusion Criteria:~* Cognitive impairment which can be attributed to another underlying medical condition that renders a possibility of Alzheimer's disease very unlikely (thus violating preamble B)~* Clinically significant Depression (decided upon clinical assessment)~* MRI exclusion criteria~* PET exclusion criteria~  1. Allergy to Flutemetamol or any of the excipients of the solution for injections~ 2. History of severe allergic reactions to drugs or allergens~ 3. Pregnancy or lactation

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Flutmetamol Group (Type: EXPERIMENTAL): PET-MR-Scan with 80-140 MBq Flutemetamol before observational period for diagnostic purpose

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Palliation Dysphagia Cancer Oesophagus Stent+Brachytherapy Versus Brachytherapy Only

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~Patients must fulfill all the following criteria:~1. Histologically or cytologically verified carcinoma of the oesophagus~2. Reduced ability to swallow solid food, minimum grade 1 (see page 16)~3. Age ≥ 18 years~4. Ability to understand and answer (with or without help) the study questionnaires~5. Written informed consent received~6. A Completed questionnaire received from the patient~7. One of the following criteria must be fulfilled:~   1. Advanced disease and WHO performance status ≥2~  2. Advanced disease and WHO performance status 0-1 and other therapy excluded due to medical condition~  3. Advanced disease and WHO performance status 0-1 and patient's preference~  4. Local disease and WHO performance status ≥2 and other therapy excluded due to medical condition~  5. Local disease and WHO performance status ≥2 and patient's preference~Exclusion Criteria:~1. Oesophageal stent already inserted~2. Endoscopic procedures not tolerated~3. Cannot have (additional) radiation therapy~4. Tumour location not suited for stent or brachytherapy (the upper 3 cm of oesophagus or major component in the cardia)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- A (Type: EXPERIMENTAL): Stent followed by 3 brachytherapy fractions
- B (Type: ACTIVE_COMPARATOR): 3 fractions of brachytherapy

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Rare Iron Overloads Except C282Y Homozygosity : Description and Characterization.

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion criteria:~* Biological profile suggesting hepcidin deficiency:~  * high serum iron (\> 25μmol / l) checked at least 2 times.~ * increased transferrin saturation coefficient (\> 50 %) checked at least 2 times, and calculated from transferrinemia.~* Proved hepatic iron overload: using a dosage of iron hepatic concentration either on hepatic biopsy, or by MRI according to the method of iron overload quantification. A threshold of 100 µmol / g is set.~* Patient's written consent for examination and collection of genetic data to set the diagnosis.~Non inclusion criteria:~* HFE hemochromatosis: C282Y/C282Y homozygosity~* Treatment by iterative phlebotomies (more than 2 phlebotomies)~* Hematological diseases with dyserythropoiesis and/or repeated transfusions~* Low haptoglobin level, suggesting chronic hemolysis or myelodysplasia~* Long-term iron oral and/or parenteral supplementation

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- iron overloads except C282Y homozygosity (Type: None): Patients with an iron overloads except C282Y homozygosity

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Hand-assisted Laparoscopic Surgery (HALS) for Myomectomy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~Inclusion criteria were as follows: women who had myoma-related symptoms such as menorrhagia, pelvic pressure/pain, or infertility; women who were not pregnant at the time of presentation (i.e., negative for urine pregnancy test or last menstrual period within the last 4 weeks); and women who were appropriated medical status for laparoscopic surgery (American Society of Anesthesiologists Physical Status classification 1 or 2).~Exclusion Criteria:~Exclusion criteria included any other uterine or adnexal abnormalities (e.g., abnormal endometrial thickness, and suspected ovarian or uterine malignancy), any sign of genital infection, presence of submucosal or pedunculated myoma as a dominant myoma, treatment of gonadotropin-releasing hormone (GnRH) agonist 2 months before surgery, or an inability to understand and provide written informed consent.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- HALS for myomectomy (Type: EXPERIMENTAL): Hand-assisted laparoscopic surgery for myomectomy
- Open myomectomy (Type: ACTIVE_COMPARATOR): Open surgery for myomectomy

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Capecitabine and Oxaliplatin in Treating Patients With Locally Advanced, Unresectable, or Metastatic Stomach Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Histologically or cytologically confirmed gastric cancer~  * Locally advanced, unresectable, or metastatic disease~* Measurable disease, defined as at least 1 lesion that can be accurately measured in ≥ 1 dimension as ≥ 20 mm with conventional techniques or as ≥ 10 mm with spiral CT scan~* No known brain metastases~PATIENT CHARACTERISTICS:~* ECOG performance status (PS) 0-2 or Karnofsky PS 60-100%~* WBC ≥ 3,000/mm³~* Absolute neutrophil count ≥ 1,500/mm³~* Platelet count ≥ 100,000/mm³~* Bilirubin normal~* AST/ALT ≤ 2.5 times upper limit of normal~* Creatinine ≤ 1.5 mg/dL~* Not pregnant or nursing~* Negative pregnancy test~* Fertile patients must use effective contraception during study and for 6 months after completion of study treatment~* Able to swallow~* No history of allergic reactions attributed to compounds of similar chemical or biologic composition to fluoropyrimidines or platinum chemotherapy agents~* No uncontrolled intercurrent illness including, but not limited to the following:~  * Ongoing or active infection~ * Symptomatic congestive heart failure~ * Unstable angina pectoris~ * Cardiac arrhythmia~ * Psychiatric illness or social situations that would preclude study compliance~PRIOR CONCURRENT THERAPY:~* More than 4 weeks since prior chemotherapy or radiotherapy (6 weeks for nitrosoureas or mitomycin C) and recovered~* At least 6 months since prior radiotherapy with capecitabine as a radioenhancer~* No concurrent combination antiretroviral therapy for HIV-positive patients~* No other concurrent chemotherapy~* No concurrent palliative radiotherapy~* No concurrent hormonal therapy except for the following:~  * Steroids for adrenal failure~ * Hormones for nondisease related conditions (e.g., insulin for diabetes)~ * Intermittent use of dexamethasone as an antiemetic~* No other concurrent investigational agents~* No other concurrent anticancer agents or therapies

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 120 Years
- Healthy Volunteers: f

Study Arms:
- Oxaliplatin + Capecitabine (Type: EXPERIMENTAL): Patients will receive Oxaliplatin 85 mg/m2/d on day 1, given as a 2-hour infusion in 250 mL of dextrose 5% repeated every 2 weeks. Capecitabine will be administered orally at a dose of 850 mg/m2 twice a day.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Direct Anterior Total Hip Arthroplasty (THA), in Versus Outpatients : A Prospective Monocentric Study in Rennes University Hospital.

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Unilateral primary total hip arthroplasty for hip osteoarthritis, primary or secondary osteoarthritis (dysplasia or post-traumatic) or osteonecrosis~* Good enough understanding of outpatient management and patient adherence to post-operative instructions~* Sufficient patient complicance to medical orders~* Living and hygiene conditions, at least, equivalent to the ones the hospital provides~* To be of age~* Non opposition to the protocole participation~Outpatients group :~- Patient schedulded to undergo outpatient THA~Inpatients group :~- Patient schedulded to undergo inpatient THA because of not fiting the following items :~* Less than an hour distance of a Health Center that provides appropriate care with regard to the surgery~* Rapid access to a phone~* Designated driver and caretaker available (at least the first night after discharge from the hospital) after the procedure Or turning down outpatient THA~Exclusion Criteria:~* Anaesthetic point of view :~  * ASA physical status ≥ 3 and : unstabilize disease with appropriate treatment or lack of preoperative mutual agreement between anesthesiologist and surgeon or not inconsiderable interaction between the operation and the disease or its treatment~ * Pre-operative Hb \< 12 (♀) \< 13 (♂) g/L (NB : no Hb control before discharge except if excessive blood loss ; Hb \< 10g/L contraindicates outpatient surgery)~ * Opioid chronic pre-operative therapy or opioid addiction~* Surgical point of view :~  * Ambulatory pre-operative status requiring use of two crutches or walking frame / distance walked \< 30 m~ * THA procedure for femoral neck fracture requiring~ * Additional operative technic needed~* Adult safeguarding.~Exclusion criteria applies to all in and outpatients.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: None

Study Arms:
- outpatients group (Type: None): Patient schedulded to undergo outpatient Direct Anterior Total Hip Arthroplasty
- inpatients group (Type: None): Patient schedulded to undergo inpatient Direct Anterior Total Hip Arthroplasty

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Sertraline for Preventing Post-stroke Depression and Improving Rehabilitation Outcomes

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Ischemic stroke within 3 months of study entry~* Admitted to a UPMC hospital for acute inpatient treatment or rehabilitation of stroke~* Speaks English~* Females willing to use an effective form of birth control throughout the study~Exclusion Criteria:~* Meets DSM-IV-TR criteria for a major depressive episode~* History of any bipolar disorder~* Psychotic or history of a psychotic disorder~* Meets DMS-IV TR criteria for alcohol or substance abuse or dependence criteria within 3 months of study entry~* Current treatment with antidepressant medication for any reason (e.g., anxiety disorder, neuropathic pain)~* Primary hemorrhagic stroke~* Language impairment severe enough to prevent valid neuropsychiatric assessment~* History of another CNS disease other than prior stroke or psychiatric illness (e.g., head trauma, multiple sclerosis, HIV with CNS involvement)~* Pulse \<50 or \>100 beats per minute~* Significant hyponatremia (Na \<130meq)~* Current hypothyroid state~* Medically unstable including symptoms of delirium (determined by review of the subject's medical status with the treating (clinical) physician; standard blood chemistry lab work will be obtained if not checked within the preceding 30 days)~* History of sensitivity to sertraline~* Pregnant or breastfeeding

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: ACTIVE_COMPARATOR): Sertraline
- 2 (Type: PLACEBO_COMPARATOR): matching placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Impact of Treatment of Periodontis on Endothelial Function in Patients With Obstructive Sleep Apnea

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* severe OSA defined by an apnea hypopnea index \> or = 30 per hour~* with or without chronic parodontitis~Exclusion Criteria:~* non equilibrated diabetes~* obesity (BMI \> or = 40)~* active smoker (\> 1 pack per day (20 cigarettes))~* pregnancy~* antibiotics within the preceding three months~* prophylactic antibiotherapy required for the parodontitis treatment~* acute parodontitis or all parontal pathology requiring immediate therapy~* less than 10 teeth

- Gender: ALL
- Minimum Age: 30 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Obstructive sleep apnea with chronic parodontis (Type: EXPERIMENTAL): patients with severe obstructive sleep apnea (OSA) and chronic parodontis treated for OSA by continuous positive airway pressure (CPAP) and intensive periodontal treatment
- Obstructive sleep apnea without chronic parodontis (Type: NO_INTERVENTION): patients with severe OSA treated by CPAP

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Organoids From Metastases of Prostate Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patient with metastatic prostate cancer~* Patient having a biopsy programmed as part of his care.~* Patient having a biopsy programmed as part of hiscare.~* Patient with sufficient tumor volume after imaging data review by the radiologist to guarantee a sufficient quantity of material for the diagnosis of biopsy and additional material for the study.~* INR \<1.5; Platelets \> 50000 / μL~Exclusion Criteria:~* Patient under age of 18 years.~* Patient under Plavix or Effient or Ticlid without possibility of suspension for 5 days, low molecular weight heparin without possibility of suspension of the dose before the intervention, or Fondaparinux without possibility of suspension, or ReoPro without possibility of suspension for 24h and aPTT \<50s and ACT \<150s, or Integrilin or Aggrastat or Argatroban without possibility of suspension 4 H before the intervention, or Angiomax without possibility of suspending 2H to 3H if CrCL\> 50 mL / min or 3H to 5h if CrCL \<50 mL / min before the intervention or and Pradaxa without possibility of suspension 2 to 3 days if CrCL\> 50 mL / min or 3 to 5 days if CrCL \<50 mL / min before the procedure~* Patient under desmopressin acetate (DDAVP)~* Patient with HIV or Hepatitis C positive or Hepatitis B infection, defined by either a detection of the HBs antigen or the presence of anti HBc antibodies without HBs antibody detectable.

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Experimental (Type: EXPERIMENTAL): Extended biopsy

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy of Dexamethasone as Adjunctive Therapy to Ranibizumab in Subjects With Choroidal Neovascularization and Age-Related Macular Degeneration

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Received at least 2 and no more than 3 monthly Lucentis or Avastin injections~* Last Lucentis or Avastin was injected approximately 4 weeks prior to screening~* Visual acuity between 20/320 and 20/40~Exclusion Criteria:~* Active ocular infection~* Contraindication to pupil dilation in either eye~* Eye surgery including cataract surgery and/or laser of any type within 3 months

- Gender: ALL
- Minimum Age: 50 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 700 ug dexamethasone and ranibizumab (Type: EXPERIMENTAL): Intravitreal injection of 700 ug dexamethasone and ranibizumab into study eye
- ranibizumab and sham (Type: ACTIVE_COMPARATOR): Intravitreal injection of ranibizumab and Sham into study eye

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Virtual Prism Adaptation Therapy on Hemispatial Neglect

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* 3 months after stroke onset~* 2 or more tests indicative of hemispatial neglect in following 3 tests: 1)line bisection test, 2)Albert's test, 3)Drawing test.~* Ability to recognize the target object, hand trajectory in the immersive virtual reality~* 16 points or more in the Korean version of mini-mental state examination~Exclusion Criteria:~* Previous stroke or traumatic brain injury history~* Can not cooperate during the therapy, due to delirium or aphasia~* Unstable medical conditions~* Severe psychiatric symptoms that interfere with the therapy participation (e.g. severe depression, agitation, psychotic symptoms)~* Pregnancy~* Can not maintain sitting posture

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Study Arms:
- Virtual Prism Adaptation Therapy (Type: EXPERIMENTAL): This group will be provided with real virtual prism adaptation therapy. In the real therapy session, the hand trajectory will deviate to the right side in the virtual reality. The deviation angle will be adjusted according to the subject's adaptation. 20min-session will be provided twice a day for 5 days, then the total 10 sessions of therapy will be provided.
- Sham Therapy (Type: SHAM_COMPARATOR): The therapy is the same as the real virtual prism adaptation therapy, but there will be no deviation of the hand trajectory in the virtual reality.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: The Effect of tDCS on Subcortical Brain Functioning

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Fluent in the English language~* History of subcortical brain damage (patient group only)~* No known neurological or cognitive impairment (control group only)~Exclusion Criteria:~* Appreciable deficits in hearing~* Schizophrenia, bipolar disorder, or major depression (normal controls only)~* Any neurological disorder associated with cognitive impairment or neuroanatomic abnormality (normal controls only)~* Language-based learning disorder (normal controls only)~* Dementia or Mini-Mental State Exam \<24 for normal control participants~* Any implanted metal device (precludes use of tDCS)~* Any implanted cardiac pacemaker

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 79 Years
- Healthy Volunteers: t

Study Arms:
- Active Stimulation (Type: EXPERIMENTAL): Transcranial direct current stimulation using Anodal or Cathodal stimulation over the area of interest
- Sham Stimulation (Type: SHAM_COMPARATOR): Transcranial direct current stimulation (tDCS) that is ramped up and ramped down providing the sensation of tDCS without delivering the full amount of tDCS.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues